Literature DB >> 12590946

Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease.

L Christiaens1, L Macchi, D Herpin, D Coisne, C Duplantier, J Allal, G Mauco, A Brizard.   

Abstract

BACKGROUND: Acetylsalicylic acid, or aspirin, is widely used in secondary prevention of coronary artery diseases, but the inhibition of platelet aggregation is not uniform in all individuals.
OBJECTIVE: To investigate the prevalence of aspirin resistance at rest and during exercise in coronary artery disease patients.
MATERIALS AND METHODS: Fifty patients with stable coronary artery disease were prospectively studied. All patients received aspirin (75-300 mg/day for >1 month) and no other antiplatelet therapy. Aspirin resistance was studied, at rest and immediately after a stress test, using the standardized platelet function analyzer (PFA-100(R), Dade-Behring). Aspirin resistance was defined as a normal collagen/epinephrine closure time (<186 s).
RESULTS: Ten patients (20%) were aspirin-resistant at rest. Out of the 40 patients who were aspirin-sensitive at rest, 9 (22%) were aspirin-resistant immediately after the exercise stress test. There were no differences in aspirin sensitivity regarding gender, age, diabetes, hypertension, dyslipidemia, platelet count, medical treatment or number of the coronary arteries involved.
CONCLUSIONS: Aspirin resistance is detected, at rest, in 20% of our patients with stable coronary artery disease. Aspirin treatment does not seem to protect against exercise-induced platelet activation in 22% of such patients, despite aspirin sensitivity at rest.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12590946     DOI: 10.1016/s0049-3848(03)00008-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

Authors:  Burak Pamukcu; Huseyin Oflaz; Rezzan Deniz Acar; Sabahattin Umman; Nevres Koylan; Berrin Umman; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

2.  Evaluation of platelet function in aspirin treated patients with CAD.

Authors:  Marlene S Williams; Thomas S Kickler; Dhananjay Vaidya; Ladina S Ng'alla; David E Bush
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

3.  Aspirin resistance: Fact or fiction? A point of view.

Authors:  Jawahar L Mehta; Bhavna Mohandas
Journal:  World J Cardiol       Date:  2010-09-26

Review 4.  Thrombosis, physical activity, and acute coronary syndromes.

Authors:  Arun Kumar; Subrata Kar; William P Fay
Journal:  J Appl Physiol (1985)       Date:  2011-05-19

Review 5.  Resistance to antiplatelet therapy.

Authors:  Sasidhar Guthikonda; Eli I Lev; Neal S Kleiman
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

Review 6.  Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.

Authors:  Rakesh K Sharma; Hanumanth K Reddy; Vibhuti N Singh; Rohit Sharma; Donald J Voelker; Girish Bhatt
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

Review 7.  Aspirin and clopidogrel response variability: review of the published literature.

Authors:  Angela D Ferguson; Hisham Dokainish; Nasser Lakkis
Journal:  Tex Heart Inst J       Date:  2008

8.  [Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].

Authors:  M Nosul; G F Kolb
Journal:  Z Gerontol Geriatr       Date:  2014-11       Impact factor: 1.281

9.  Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease.

Authors:  A R Muir; M F McMullin; C Patterson; P P McKeown
Journal:  Heart       Date:  2008-08-12       Impact factor: 5.994

10.  Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease.

Authors:  Xian-Feng Liu; Jian Cao; Li Fan; Lin Liu; Jian Li; Guo-Liang Hu; Yi-Xin Hu; Xiao-Li Li
Journal:  J Geriatr Cardiol       Date:  2013-03       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.